Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel long-term safety in MDD
NCT03002077Phase 3Completed
- Sponsor
- Allergan
- Start
- Feb 2017
- Primary completion
- Dec 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rapastinel in major depressive disorder (MDD), sponsored by Allergan. Primary endpoint: Treatment-Emergent Adverse Events at 52 weeks. Started Feb 2017; status: completed.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03002077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002077.